Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042384 | 0.80 | RIPK1 (0.46) | RIPK1AOC3 | |
| SCHEMBL17073447 | 0.77 | RIPK1 (0.53) | RIPK1ALOX15LMNAKDM4EL3MBTL1 | |
| SCHEMBL3389847 | 0.76 | MEN1 (0.45) | CYP1A2MEN1KMT2A | |
| SCHEMBL5231376 | 0.76 | TSHR (0.39) | CYP1A2CYP2D6MEN1KMT2A | |
| SCHEMBL639359 | 0.76 | ESR1 (0.35) | LMNAKDM4ECYP1A2CYP2D6MEN1 | |
| SCHEMBL3081755 | 0.75 | RIPK1 (0.64) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL5185803 | 0.75 | RIPK1 (0.64) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL6337980 | 0.74 | ACP3 (0.37) | L3MBTL1CYP1A2 | |
| SCHEMBL1521003 | 0.73 | KDM4E (0.49) | RIPK1ALOX15KDM4ECYP1A2CYP2D6 | |
| SCHEMBL18632428 | 0.73 | RIPK1 (0.49) | RIPK1ALOX15LMNAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371383-A1 | PYRIDIN-2-YL ALKYLAMINO SUBSTITUTED HYDROXAMIC ACID AND USES THEREOF | HAWAII BIOTECH, INC. | 2021-12-02 | — | — | US | disclosed |
| US-8119692-B2 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286125-A1 | Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning | ANTXR2, ABAT, BAX | RIPK1 4354/4885ALOX15 128/4885LMNA 2360/4885 |
| US-20210371383-A1 | PYRIDIN-2-YL ALKYLAMINO SUBSTITUTED HYDROXAMIC ACID AND USES THEREOF | H1-5, HCAR3, H1-3 | RIPK1 4446/4885ALOX15 255/4885LMNA 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.